Fundraising Fox
Syngoi
AcquiredWatertown, US · 3 known investors
Find your way into Syngoi
Artis BioSolutions is an integrated platform for genetic medicine that produces enzymatically synthesized synthetic DNA and develops it into clinical-grade advanced therapies with in-house GMP manufacturing. It serves developers of advanced therapy medicinal products across modalities such as mRNA, gene editing, viral vectors, cell therapies, and vaccines, with production sites in Watertown, MA (US) and Bilbao, Spain (EU).
Investors · 3
Asahi Kasei Corporate Venture Capitallisted by Asahi Kasei Corporate Venture CapitalMenlo Park · $200K – $5M
How we know: Asahi Kasei Corporate Venture Capital's portfolio page · Not right? Tell us
Buenavista Equity Partnerslisted by Buenavista Equity PartnersMadrid
How we know: Buenavista Equity Partners's portfolio page · Not right? Tell us
Columbus Venture PartnersreportedValenciavia Jose Mesa · inferred
How we know: the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Syngoi do?
- Artis BioSolutions is an integrated platform for genetic medicine that produces enzymatically synthesized synthetic DNA and develops it into clinical-grade advanced therapies with in-house GMP manufacturing. It serves developers of advanced therapy medicinal products across modalities such as mRNA, gene editing, viral vectors, cell therapies, and vaccines, with production sites in Watertown, MA (US) and Bilbao, Spain (EU).
- Who are Syngoi's investors?
- Syngoi's investors include Asahi Kasei Corporate Venture Capital, Buenavista Equity Partners, Columbus Venture Partners.
- Where is Syngoi headquartered?
- Syngoi is headquartered in Watertown, US.